Althea building site for highly active bioproduction and ADCs

By Fiona BARRY contact

- Last updated on GMT

The US has limited capacity for high containment manufacturing, said Althea's ADC expert
The US has limited capacity for high containment manufacturing, said Althea's ADC expert

Related tags: Dna

CDMO Ajinomoto Althea is opening a new facility to offer outsourced ADC (antibody drug conjugate) and HPAPI (highly potent active pharmaceutical ingredient) manufacturing, the Californian company has announced.

The contract development and manufacturing organisation has begun retrofitting a facility it bought in May near its existing site in San Diego. It plans to open the site in Q2 2016, with full operations at the start of 2017.

The finished 57,000 sq ft plant will offer bioconjugation, formulation, purification, quality control, and aseptic fill-finish including lyophilisation. Construction includes measures for safe handling of very low OEL (Occupational Exposure Limit) compounds under high containment, aseptic and GMP conditions.

US ‘lacks high containment’ sites

Althea said the site will offer clients contract services from early clinical phase to commercialisation.

Althea’s head of ADCs, Jason Brady, said “Currently, there is limited capacity of high containment manufacturing in the United States.  Althea is excited to make this significant expansion of our service offerings to address the needs of the ADC market as well as other highly potent products.  Given our existing core capabilities in complex biologics formulation and aseptic filling, this investment in ADC and HPAPI fill finish manufacturing is a natural progression and logical step for Althea​.”

Ajinomoto Althea was formed in 2013 when Tokyo-based chemical company Ajinomoto bought US CDMO Althea for $175m, including its biopharmaceutical production capabilities for microbial-derived recombinant proteins and plasmid DNA, upstream and downstream process development, analytical development, lyophilisation cycle, complex formulation, product release, ICH stability testing and cGMP vial and syringe filling.

Related news

Show more

Related products

show more

Rapid Biosafety Testing Enables the Future of Manufacturing

Rapid Biosafety Testing Enables the Future of Manufacturing

Viral Safety for mAb: Prevent, Detect, Remove | 05-Aug-2020 | Technical / White Paper

Traditional methods for adventitious agent testing rely on biological amplification and detection, which can take several weeks. This time-consuming approach...

Related suppliers

Follow us

Products

View more

Webinars